Publications

Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer

Download PDF
Resource: Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer

.

Related Articles

Biphasic Myoepithelial Carcinoma With 5p/5q Loss

Link
Integrative multi-omics reveals two biologically distinct groups of pilocytic astrocytoma

Link